-
TSP50 promotes the proliferation, migration and invasion of gastric cancer cells involving NF-kappaB dependent EMT activation. Targeting TSP50 may provide a novel therapeutic strategy for the management of gastric cancer
-
human epidermal growth factor receptor 2 (HER-2) levels, were correlated well with TSP50/p-Samd2/3 and TSP50/p27 expression status. Thus, our studies revealed a novel regulatory mechanism underlying TSP50-induced cell proliferation and provided a new favorable intervention target for the treatment of breast cancer
-
In patients with Colon cancer, the expression of TSP50 gene was associated with a poor prognosis.
-
TSP50 plays a significant role in NSCLC cell proliferation and may act as a novel oncogene in the development and progression of NSCLC.
-
Results suggest that 7P3A, which consists of 70 % 25-methoxyl-dammarane-3beta, 12beta, 20-triol and 30 % artemisinin, exhibits anti-cancer effects, in part, through downregulation of testes-specific protease 50 (TSP50) expression.
-
Results show that TSP50 is up-regulated in laryngocarcinoma tumour tissues and its down-regulation inhibits cell proliferation, reduces cell migration and induces cell apoptosis of laryngocarcinoma in NF-KB mediated pathway.
-
we found that some breast cancer diagnosis-associated features such as tumor size, tumor grade, estrogen receptors (ER) and progesterone receptors (PR) levels, were correlated well with TSP50/p65 and TSP50/MMP9 expression status
-
TSP50's threonine protease activity is crucial for its effects on tumor formation.
-
The mutations in the catalytic triad of TSP50 could significantly depressed TSP50-mediated cell proliferation and tumor formation.
-
High TSP50 expression is associated with laryngocarcinoma.
-
the importance of threonine 310, the most critical protease catalytic site in TSP50, to TSP50-induced cell proliferation and tumor formation
-
TSP50 is a potential effective indicator of poor survival for colorectal carcinoma patients, especially for those with early-stage tumors.
-
Results strongly suggest that bFGF mediates TSP50 downregulation by ERK1/2 activation, leading to the phosphorylation of Sp1 in this process.
-
TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells.
-
TSP50 was largely downregulated in all testicular germ cell tumors. It may function in mammalian spermatogenesis. Its linear catalytic structure is similar to many serine proteases, except for a Thr-for-Ser residual catalytic site substitution.
-
Overexpression of Sp1 and C/EBPbeta transcriptional factors upregulated the activities of the TSP50 promoter.
-
These findings suggested that DNA methylation might regulate the TSP50 and mTSP50 gene expressions in different types of tissues and spermatic cells.